Breast Cancer Clinical Trial
— RIVAGEOfficial title:
Cognitive Processing Slowness as a Marker of Cognitive Impairment in Non-central Nervous System Cancer Patients
Cancer is a frequent disease considering that one person out of three will be confronted with it in their lifetime. Cancer patients often express complaints related to cognitive impairment as an outcome of their oncological treatment. These cognitive disorders have a significant impact on the patient's and their carer's quality of life. Therefore, it appears necessary to have a reliable, quick and simple tool in order to detect cognitive impairment. The rationale of this study relies on 3 main points : - The cognitive complaint frequently reported by cancer patients - The difficulty in reliably demonstrating the cause of this complaint through conventional neuropsychological tests - The interest of cognitive processing speed as an indicator of cognitive dysfunction The primary objective of the study is to evaluate a potential variation of cognitive processing speed at the Saint-Louis Lille Battery (SSLIB) between the beginning and during (4 months after the beginning) the oncological treatment of adults with breast cancer or colon cancer.
Status | Not yet recruiting |
Enrollment | 200 |
Est. completion date | April 1, 2026 |
Est. primary completion date | August 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 70 Years |
Eligibility | Inclusion Criteria: - Beginning an oncological treatment for breast or colon cancer - Patients of age = 20 and = 70 years old - Cancer diagnosis announcement delivered since less than 3 weeks (+/- a week) - Patient affiliated to French social security Exclusion Criteria: - Patient's opposition to the study - Notion of an abnormal cerebral scan or MRI - Drug use (alcohol, narcotics…) - Chronic (= 15 days) treatment with corticosteroids > 1mg/kg/j (prednisone or equivalent) - Ocular pathology or cognitive disorder impairing comprehension and reading abilities - Patients under curatorship, guardianship or under the protection of justice |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients for which there is a variation of reaction time between the beginning and during the oncological treatment at M4 | The variation will be defined as follows :
Mild if the reaction times vary for only one of the Saint-Louis Lille Battery (SLLIB) tests Moderate if the variation appears on two of the SLLIB tests Severe if the variation appears on three of the SLLIB tests |
At 4 months | |
Secondary | Proportion of patients for which there is a variation of reaction time between the beginning and after the end of the oncological treatment (M12) | The variation will be defined as follows :
Mild if the reaction times vary for only one of the Saint-Louis Lille Battery (SLLIB) tests Moderate if the variation appears on two of the SLLIB tests Severe if the variation appears on three of the SLLIB tests |
At 12 months | |
Secondary | Proportion of patients for which there is a variation of reaction time between M4 and M12 | The variation will be defined as follows :
Mild if the reaction times vary for only one of the Saint-Louis Lille Battery (SLLIB) tests Moderate if the variation appears on two of the SLLIB tests Severe if the variation appears on three of the SLLIB tests |
At 12 months | |
Secondary | Anxiety and depression levels | Anxiety and depression levels will be assessed using the Hamilton Anxiety Depression scale : The HAD scale is a self-assessment scale for detecting states of depression and anxiety in the setting of an hospital medical outpatient clinic.
HADS is a self-administered scale of 14 items which assessed levels of depression and anxiety, divided into 2 subscales of 7 items (Anxiety or HADS-A, Depression or HADS-D). Each item is scored on a scale of 0 to 3. A score is generated for each of the two sub-scales (sum of the 7 items, ranging from 0 to 21). Limit scores, for each of the scores, distinguish: non-cases or asymptomatic ones (score = 7); probable or borderline cases (score 8-10); clearly or clinically symptomatic cases (score = 11). |
At inclusion | |
Secondary | Anxiety and depression levels | Anxiety and depression levels will be assessed using the Hamilton Anxiety Depression scale : The HAD scale is a self-assessment scale for detecting states of depression and anxiety in the setting of an hospital medical outpatient clinic.
HADS is a self-administered scale of 14 items which assessed levels of depression and anxiety, divided into 2 subscales of 7 items (Anxiety or HADS-A, Depression or HADS-D). Each item is scored on a scale of 0 to 3. A score is generated for each of the two sub-scales (sum of the 7 items, ranging from 0 to 21). Limit scores, for each of the scores, distinguish: non-cases or asymptomatic ones (score = 7); probable or borderline cases (score 8-10); clearly or clinically symptomatic cases (score = 11). |
At 4 months | |
Secondary | Anxiety and depression levels | Anxiety and depression levels will be assessed using the Hamilton Anxiety Depression scale : The HAD scale is a self-assessment scale for detecting states of depression and anxiety in the setting of an hospital medical outpatient clinic.
HADS is a self-administered scale of 14 items which assessed levels of depression and anxiety, divided into 2 subscales of 7 items (Anxiety or HADS-A, Depression or HADS-D). Each item is scored on a scale of 0 to 3. A score is generated for each of the two sub-scales (sum of the 7 items, ranging from 0 to 21). Limit scores, for each of the scores, distinguish: non-cases or asymptomatic ones (score = 7); probable or borderline cases (score 8-10); clearly or clinically symptomatic cases (score = 11). |
At 12 months | |
Secondary | Cognitive complaint | Cognitive complaint will be assessed using the Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) questionnaire v3.
It is made up 37 items divided in four subscales: perceived cognitive impairments (PCI); perceived cognitive abilities ; impact of perceived cognitive impairment on Quality Of Life; and comments from others on cognitive function. It ranges from 0 to 148. The higher the score, the better the cognitive function. |
At inclusion | |
Secondary | Cognitive complaint | Cognitive complaint will be assessed using the Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) questionnaire v3.
It is made up 37 items divided in four subscales: perceived cognitive impairments (PCI); perceived cognitive abilities ; impact of perceived cognitive impairment on Quality Of Life; and comments from others on cognitive function. It ranges from 0 to 148. The higher the score, the better the cognitive function. |
At 4 months | |
Secondary | Cognitive complaint | Cognitive complaint will be assessed using the Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) questionnaire v3.
It is made up 37 items divided in four subscales: perceived cognitive impairments (PCI); perceived cognitive abilities ; impact of perceived cognitive impairment on Quality Of Life; and comments from others on cognitive function. It ranges from 0 to 148. The higher the score, the better the cognitive function. |
At 12 months | |
Secondary | Quality of life assessed with the QLQ-C30 questionnaire | Quality of life evaluated using questionnaire "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire" (EORTC QLQ-C30- v3). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. A high score for a functional scale represents a high/healthy level of functioning. A high score for the global health status/ QoL represents a high QoL and a high score for a symptom scale/item represents a high level of symptomatology/problems. | At inclusion | |
Secondary | Quality of life assessed with the QLQ-C30 questionnaire | Quality of life evaluated using questionnaire "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire" (EORTC QLQ-C30- v3). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. A high score for a functional scale represents a high/healthy level of functioning. A high score for the global health status/ QoL represents a high QoL and a high score for a symptom scale/item represents a high level of symptomatology/problems. | At 4 months | |
Secondary | Quality of life assessed with the QLQ-C30 questionnaire | Quality of life evaluated using questionnaire "European Organization for Research and Treatment of Cancer Quality of Life Questionnaire" (EORTC QLQ-C30- v3). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. A high score for a functional scale represents a high/healthy level of functioning. A high score for the global health status/ QoL represents a high QoL and a high score for a symptom scale/item represents a high level of symptomatology/problems. | At 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |